Increased Risk of Papillary Thyroid Cancer in Celiac Disease

2006 ◽  
Vol 51 (10) ◽  
pp. 1875-1877 ◽  
Author(s):  
Laura Kent ◽  
Russell McBride ◽  
Robert McConnell ◽  
Alfred I. Neugut ◽  
Govind Bhagat ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Celiac Disease ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Increased Risk

INCREASED RISK OF PAPILLARY THYROID CANCER IN CELIAC DISEASE

2004 ◽  
Vol 99 ◽  
pp. S67
Author(s):  
Laura K. Kent ◽  
Peter H.R. Green ◽  
Russell McBride ◽  
Alfred I. Neugut ◽  
Robert J. McConnell
Keyword(s):  
Thyroid Cancer ◽  
Celiac Disease ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Increased Risk

scholarly journals Case Report: Papillary Thyroid Cancer in a Patient with Celiac Disease and Thalassemia Trait

2020 ◽  
Vol 13 (3) ◽  
pp. 1364-1367
Author(s):  
Afaf Albattah ◽  
Yahia Imam ◽  
Ahmed Osman Saleh ◽  
Khalid Ahmed ◽  
Tarek Aboursheid ◽  
...  
Keyword(s):  
Risk Factors ◽  
Thyroid Cancer ◽  
Celiac Disease ◽  
Case Report ◽  
Papillary Thyroid Cancer ◽  
Thalassemia Major ◽  
Papillary Thyroid ◽  
Unique Case ◽  
Thalassemia Trait ◽  
Common Risk Factors

Thyroid cancer is the most frequent endocrine neoplasm in the general population. Common risk factors include gender, radiation exposure, and genetic backgrounds. The association of papillary thyroid cancer and celiac disease has frequently been reported in the literature; however, the association of papillary thyroid cancer and thalassemia trait is rare. Likewise, the association of thalassemia major and celiac disease is also rare. We hereby report a unique case of papillary thyroid cancer in a patient with celiac disease and thalassemia trait.

Male Patients With Papillary Thyroid Cancer Have a Higher Risk of Extranodal Extension

2021 ◽  
Author(s):  
Hu Hei ◽  
Bin Zhou ◽  
Wenbo Gong ◽  
Chen Zheng ◽  
Jianwu Qin
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Multivariable Analysis ◽  
Underlying Mechanism ◽  
Clinicopathological Factors ◽  
Papillary Thyroid ◽  
Extranodal Extension ◽  
Increased Risk ◽  
Male Patients ◽  
Male Sex

Abstract Purpose: There is a sex disparity in papillary thyroid cancer (PTC). Male sex is associated with a higher likelihood of advanced stage disease. This study aimed to examine the significance of sex for extranodal extension (ENE) in PTC. Patients and Methods: We reviewed the data of PTC patients who had undergone initial surgical resection from July 2012 to December 2014 (N = 1531). The effects of sex and other clinicopathological factors on ENE were investigated.Results: Of 1531 patients identified, 377 (24.6%) were male, 816 (53.3%) had positive nodes, and 256 (16.7%) had ENE. Compared with female patients, male patients had a higher risk of ENE (P < 0.001). Multivariable analysis of clinicopathological factors revealed that male sex (odds ratio [OR], 1.98; 95% confidence interval [CI], 1.37 - 2.87; P < 0.001), age older than 60 years (OR, 1.93; 95% CI, 1.08 - 3.35; P = 0.023), extrathyroidal extension (OR, 3.52; 95% CI, 2.42 - 5.14; P < 0.001), bilateral multifocality (OR, 2.18; 95% CI, 1.53 - 3.13; P < 0.001), and more positive nodes were significantly associated with increased risk of ENE. Patients with 6-10 positive nodes were 16.45-fold higher to have ENE than patients with 5 positive nodes or less (95% CI, 11.07 - 24.68; P < 0.001).Conclusion: Male PTC patients had a higher risk of ENE than female. Sex was an independent predictor of ENE. The underlying mechanism needs to be investigated further.

scholarly journals Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy

2020 ◽  
Vol 9 (8) ◽  
pp. 2481
Author(s):  
Kirk Jensen ◽  
Shilpa Thakur ◽  
Aneeta Patel ◽  
Maria Cecilia Mendonca-Torres ◽  
John Costello ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Liquid Biopsy ◽  
Digital Pcr ◽  
Response To Therapy ◽  
Response To Treatment ◽  
Papillary Thyroid ◽  
Primary Tumors ◽  
Promising Tool ◽  
Increased Risk

The detection of rare mutational targets in plasma (liquid biopsy) has emerged as a promising tool for the assessment of patients with cancer. We determined the presence of cell-free DNA containing the BRAFV600E mutations (cfBRAFV600E) in plasma samples from 57 patients with papillary thyroid cancer (PTC) with somatic BRAFV600E mutation-positive primary tumors using microfluidic digital PCR, and co-amplification at lower denaturation temperature (COLD) PCR. Mutant cfBRAFV600E alleles were detected in 24/57 (42.1%) of the examined patients. The presence of cfBRAFV600E was significantly associated with tumor size (p = 0.03), multifocal patterns of growth (p = 0.03), the presence of extrathyroidal gross extension (p = 0.02) and the presence of pulmonary micrometastases (p = 0.04). In patients with low-, intermediate- and high-risk PTCs, cfBRAFV600E was detected in 4/19 (21.0%), 8/22 (36.3%) and 12/16 (75.0%) of cases, respectively. Patients with detectable cfBRAFV600E were characterized by a 4.68 times higher likelihood of non-excellent response to therapy, as compared to patients without detectable cfBRAFV600E (OR (odds ratios), 4.68; 95% CI (confidence intervals)) 1.26–17.32; p = 0.02). In summary, the combination of digital polymerase chain reaction (dPCR) with COLD-PCR enables the detection of BRAFV600E in the liquid biopsy from patients with PTCs and could prove useful for the identification of patients with PTC at an increased risk for a structurally or biochemically incomplete or indeterminate response to treatment.

scholarly journals BRAFV600E Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence

2020 ◽  
Vol 44 (8) ◽  
pp. 2685-2691 ◽  
Author(s):  
Samuel Enumah ◽  
Abbey Fingeret ◽  
Sareh Parangi ◽  
Dora Dias-Santagata ◽  
Peter M. Sadow ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Recurrence ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Increased Risk ◽  
Thyroid Cancer Recurrence

BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer

Surgery ◽  
2010 ◽  
Vol 148 (6) ◽  
pp. 1139-1146 ◽  
Author(s):  
Christine J. O’Neill ◽  
Martyn Bullock ◽  
Angela Chou ◽  
Stan B. Sidhu ◽  
Leigh W. Delbridge ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Reoperative Surgery ◽  
Nodal Recurrence ◽  
Increased Risk

scholarly journals Impact of BMI on Complications and Satisfaction in Patients With Papillary Thyroid Cancer and Lateral Neck Metastasis

2019 ◽  
Vol 26 (1) ◽  
pp. 107327481985383 ◽  
Author(s):  
Qiu-feng Jin ◽  
Qi-gen Fang ◽  
Jin-xing Qi ◽  
Peng Li
Keyword(s):  
Thyroid Cancer ◽  
Neck Dissection ◽  
Papillary Thyroid Cancer ◽  
Population Characteristics ◽  
Obese Patients ◽  
Lateral Neck ◽  
Papillary Thyroid ◽  
Lateral Neck Dissection ◽  
Subjective Satisfaction ◽  
Increased Risk

Background: This study investigates the effect of body mass index (BMI) on complications and satisfaction in patients who underwent thyroidectomy and lateral neck dissection. Methods: We retrospectively reviewed 386 patients with papillary thyroid cancer who underwent total thyroidectomy and lateral neck dissection between January 2013 and December 2016. We compared variables including population characteristics, subjective satisfaction, and complications in nonobese (BMI < 28.0 kg/m2) and obese (BMI ≥ 28.0 kg/m2) patients. Results: Obesity was associated with an increased risk of postoperative hemorrhage (POH) ( P = .014), accessory nerve injury ( P < .001), operative time ( P < .001) and infection ( P = .013). However, obese patients had higher subjective satisfaction and Vancouver Scar Scale (VSS) scores ( P < .05). Conclusions: Obesity was associated with increased risk of POH, injury of the SAN, and infection. Interestingly, we found that obese patients had higher subjective satisfaction and VSS scores.

scholarly journals Proteomics study of serum exosomes from papillary thyroid cancer patients

2018 ◽  
Vol 25 (10) ◽  
pp. 879-891 ◽  
Author(s):  
Dan Luo ◽  
Shaohua Zhan ◽  
Wenchao Xia ◽  
Liang Huang ◽  
Wei Ge ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Papillary Thyroid Cancer ◽  
Cancer Cell ◽  
Lymph Node Metastases ◽  
Tandem Mass ◽  
Papillary Thyroid ◽  
Increased Risk ◽  
Node Metastases ◽  
Serum Exosomes

Lymph node metastasis (LNM) in papillary thyroid cancer (PTC) is related to increased risk of recurrence and poor prognosis. Tumour exosomes have been shown to be associated with metastasis of cancer cells. Therefore, we aim to identify the characteristics and biological functions of serum exosomes in lymph node metastases of PTC. We compared proteome profiles of serum-purified exosomes (SPEs) from PTC patients with LNM, PTC patients without LNM, and healthy donors, using a combination of liquid chromatography-tandem mass spectroscopy analyses and tandem mass tag label quantitation analysis. We identified 1569 proteins by two or more unique peptides. Compared with the SPEs of PTC patients without LNM, we found 697 differentially expressed proteins in the SPEs of PTC patients with LNM. Our results revealed overexpression of specific proteins with well-established links to cancer cell metastasis, such as SRC, TLN1, ITGB2 and CAPNS1. Consistent with mass spectrum results, we performed Western blot to detect the expression of these proteins in individual sample. Biological pathway analyses showed that integrin signalling was aberrantly activated in the SPEs of PTC patients with LNM compared to those without LNM. Our study reveals that SPEs of PTC patients with lymph node metastases promote BHT101 thyroid cancer cell invasiveness, but have no apparent influence on cell migration. In the serum exosomes of PTC patients with LNM, integrin-associated proteins are obviously upregulated. These proteomic findings will contribute to elucidation of the pathophysiological functions of tumour-derived exosomes.

scholarly journals Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Mayumi Endo ◽  
Jessica B. Liu ◽  
Marcelle Dougan ◽  
Jennifer S. Lee
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Incidence Rates ◽  
Lymphocytic Leukemia ◽  
Second Primary ◽  
Papillary Thyroid ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Increased Risk ◽  
End Results

Increased risk of second primary malignancy (SPM) in papillary thyroid cancer (PTC) has been reported. Here, we present the most updated incidence rates of second primary malignancy from original diagnosis of PTC by using the data from the Surveillance, Epidemiology, and End Results. In this cohort, 3,200 patients developed SPM, a substantially higher number than in the reference population of 2,749 with observed to expected ratio (O/E) of 1.16 (95% CI; 1.12–1.21). Bone and joint cancer had the highest O/E ratio of 4.26 (95% confidence interval [CI] 2.33–7.15) followed by salivary gland (O/E 4.15; 95% CI 2.76–6.0) and acute lymphocytic leukemia (O/E 3.98; 95% CI 2.12–6.8). Mean age at the diagnosis of SPM was 64.4 years old. Interestingly, incidence of colorectal cancer was lower in thyroid cancer survivors compared to general population (large intestine O/E 0.3; 95% CI 0.06–0.88, rectum O/E 0.6; 95% CI 0.41–0.85); however, this was not observed in patients who underwent radiation therapy. The incidence of SPM at all sites was higher during 2000–2012 compared to 1992–1999 (O/E 1.24 versus 1.10). Surprisingly, patients with micropapillary cancer had higher incidence of SPM than counterparts with a larger tumor in radiation group (O/E of 1.40 versus 1.15). O/E of all cancers were higher in males compared to females with O/E of 1.41 versus 1.17 during the period of 2000–2012. Diagnosis of PTC before age 50, especially at age 30–34, was associated with higher incidence of overall SPM (age 30–34; O/E 1.43; 95% CI; 1.19–1.71). Efficient monitoring strategies that include age at the time of thyroid cancer diagnosis, exposure to radiation, gender, and genetic susceptibility may successfully detect SPM earlier in the disease course. This is especially important given the excellent prognosis of the initial thyroid cancer itself.

Sign in / Sign up

Export Citation Format

Share Document